Previous 10 | Next 10 |
Revenue of $964.0 million; 36% reported growth; 34% organic growth GAAP EPS from continuing operations of $1.57; Adjusted EPS of $2.09 PerkinElmer, Inc . (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial resu...
The best sectors to focus your attention on now. The highest-rated stocks worth adding to your watch list. Why high-volatility ahead of elections could create a great buy opportunity. For further details see: If Stocks Tumble On Election Worries, Here Are The Top Stocks ...
PerkinElmer (NYSE:PKI) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $1.49 (+40.6% Y/Y) and the consensus Revenue Estimate is $837.16M (+18.4% Y/Y).Over the last 2 years, PKI has beaten EPS estimates 75% of the time a...
PerkinElmer (PKI) announces CE Mark certification of its PKamp Respiratory SARS-CoV-2 RT-PCR Panel that differentiates between SARS-CoV-2, influenza A viruses, influenza B viruses and respiratory syncytial virus ((RSV)) in a single assay from a single nasopharyngeal, oropharyngeal or nasal sw...
Company’s latest test enables differential diagnosis between COVID-19, flu and RSV infection PerkinElmer, Inc. (NYSE: PKI) announced today that its PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel has received clearance to be marketed as an in vitro diagnosti...
PerkinElmer (PKI) declares $0.07/share quarterly dividend, in line with previous.Forward yield 0.22%Payable Feb. 12; for shareholders of record Jan. 22; ex-div Jan. 21.See PKI Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: PerkinElmer declares $0.07 div...
Findings shared on open data portal to help in global pursuit of drug repurposing candidates for COVID-19 PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that a research team at the National Center for Advancin...
Abcam has filed to raise capital in a U.S. IPO. The firm sells or licenses reagents and antibodies to biopharmaceutical research organizations worldwide. While the firm has seen a recent contraction in revenue due to Covid-19, I suspect this is temporary; ABCM is well position...
The table in the release was incorrect. The corrected table should read: PerkinElmer, Inc: (1) amounts may not sum due to rounding The updated release reads: PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020 PerkinE...
PerkinElmer, Inc. (NYSE: PKI) , a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of approximately 35% and 33%, respectively, for the third quarter ended October 4, 2020. The strong revenue ...
News, Short Squeeze, Breakout and More Instantly...
Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin tradi...
Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world’s greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on ...
2023-05-07 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...